Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 113-124

  Hendrickson, Ronald C ^a   Cicinnati, Vito R ^c,d   Albers, Andreas ^c,d   Dworacki, Grzegorz ^c,d   Gambotto, Andrea ^e   Pagliano, Ornella ^c,d   Tüting, Thomas ^c,d   Mayordomo, Jose I ^c,d   Visus, Carmen ^c,d   Appella, Ettore ^e   Shabanowitz, Jeffrey ^a   Hunt, Donald F ^a,b   Deleo, Albert B ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CTL; Hsd17b12; Mass spectrometry; Meth A; Peptides

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; PEPTIDE VACCINE; PLASMID VECTOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 12; TUMOR REJECTION PEPTIDE; UNCLASSIFIED DRUG; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; CANCER VACCINE; HISTOCOMPATIBILITY ANTIGEN; HYDROXYSTEROID DEHYDROGENASE; PEPTIDE; TUMOR ANTIGEN; TUMOR ASSOCIATED TRANSPLANTATION ANTIGEN; TUMOR-ASSOCIATED TRANSPLANTATION ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENOMICS; HUMAN; IMMUNOBLOTTING; IMMUNOGENICITY; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOGENE; SARCOMA; SPLEEN CELL; TUMOR REJECTION; ANIMAL; CYTOTOXICITY; DENDRITIC CELL; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

17-HYDROXYSTEROID DEHYDROGENASES; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PEPTIDES; PSEUDOGENES; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70350091064     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0730-7     Document Type: Article

References (45)

1. L Gross 1943 Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line Cancer Res 3 326 333
2. LJ Old EA Boyse DA Clarke E Caldwell 1962 Antigenic properties of chemically induced tumors Ann NY Acad Sci 101 80 106 10.1111/j.1749-6632.1962. tb26446.x 1:CAS:528:DyaF3sXkt1Cjs7Y%3D
3. AB DeLeo H Shiku T Takahashi M John LJ Old 1977 Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma J Exp Med 146 720 734 10.1084/jem.146.3.720 197192 1:STN:280:DyaE2s3ltFaqsA%3D%3D (Pubitemid 8175981)
4. EM Jaffee DM Pardoll 1996 Murine tumor antigens: is it worth the search? Curr Opin Immunol 8 622 627 10.1016/S0952-7915(96)80077-X 8902386 1:CAS:528:DyaK28Xmt1Ogtr4%3D (Pubitemid 26385389)
5. G Parmiani A De Filippo L Novellino C Castelli 2007 Unique human tumor antigens: immunobiology and use in clinical trials J Immunol 178 1975 1979 17277099 1:CAS:528:DC%2BD2sXht1CgtLc%3D
6. DF Hunt RA Henderson J Shabanowitz K Sakaguchi H Michel N Sevilir AL Cox E Appella VH Engelhard 1992 Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry Science 255 1261 1263 10.1126/science.1546328 1546328 1:CAS:528:DyaK38XhvFahsr0%3D
7. T Boon JC Cerottini B Van den Eynde P van der Bruggen A Van Pel 1994 Tumor antigens recognized by T lymphocytes Annu Rev Immunol 12 337 365 10.1146/annurev.iy.12.040194.002005 8011285 1:CAS:528:DyaK2cXivFKju70%3D
8. L Novellino C Castelli G Parmiani 2005 A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol Immunother 54 187 207 10.1007/s00262-004-0560-6 15309328 1:CAS:528:DC%2BD2MXjs1ahug%3D%3D (Pubitemid 40174238)
9. A Ribas LH Butterfield JA Glaspy JS Economou 2003 Current developments in cancer vaccines and cellular immunotherapy J Clin Oncol 21 2415 2432 10.1200/JCO.2003.06.041 12805342 1:CAS:528:DC%2BD2cXpsVKjsL0%3D (Pubitemid 46621880)
10. JM Kirkwood AA Tarhini MC Panelli SJ Moschos HM Zarour LH Butterfield HJ Gogas 2008 Next generation of immunotherapy for melanoma J Clin Oncol 26 3445 3455 10.1200/JCO.2007.14.6423 18612161 1:CAS:528:DC%2BD1cXpvVWitrY%3D
11. J Bilsborough A Van Pel C Uyttenhove T Boon BJ Van den Eynde 1999 Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815 J Immunol 162 3534 3540 10092811 1:CAS:528: DyaK1MXhvV2qsr8%3D
12. H Lu KL Knutson E Gad ML Disis 2006 The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens Cancer Res 66 9754 9761 10.1158/0008-5472.CAN-06-1083 17018635 1:CAS:528:DC%2BD28XhtVams7jM (Pubitemid 44623677)
13. + T cells Proc Natl Acad Sci USA 91 3171 3175 10.1073/pnas.91.8.3171 7909159 1:CAS:528:DyaK2cXjt1Sqsro%3D
14. T Matsutake PK Srivastava 2001 The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein Proc Natl Acad Sci USA 98 3992 3997 10.1073/pnas.071523398 11274422 1:CAS:528:DC%2BD3MXis1Khsbk%3D (Pubitemid 32249886)
15. A Uenaka E Nakayama 2003 Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL) Cancer Sci 94 931 936 10.1111/j.1349-7006.2003.tb01380.x 14611667 1:CAS:528:DC%2BD2cXhsF2nsQ%3D%3D (Pubitemid 37508973)
16. JI Mayordomo DJ Loftus H Sakamoto CM De Cesare PM Appasamy MT Lotze WJ Storkus E Appella AB DeLeo 1996 Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines J Exp Med 183 1357 1365 10.1084/jem.183.4.1357 8666894 1:CAS:528:DyaK28XisFenur4%3D (Pubitemid 26134279)
17. AB DeLeo TL Whiteside 2008 Development of multi-epitope vaccines targeting wild-type sequence p53 peptides Expert Rev Vaccines 7 1031 1045 10.1586/14760584.7.7.1031 18767952 1:CAS:528:DC%2BD1cXhtVOiur%2FM
18. + cytotoxic T lymphocyte Cancer Res 55 124 128 7528638 1:CAS:528:DyaK2MXivVGnsr8%3D
19. S Shu T Chou SA Rosenberg 1986 In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells J Immunol 136 3891 3896 3486223 1:CAS:528:DyaL28Xit1ejs7s%3D
20. P Dubey RC Hendrickson SC Meredith CT Siegel J Shabanowitz JC Skipper VH Engelhard DF Hunt H Schreiber 1997 The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68 J Exp Med 185 695 705 10.1084/jem.185.4.695 9034148 1:CAS:528:DyaK2sXhtlWnu7g%3D (Pubitemid 27098154)
21. Hendrickson RC, Skipper JC, Shabanowitz J, Slingluff CJ Jr, Engelhard VH, Hunt DF (1997) Use of tandem mass spectrometry for MHC ligand analysis. In: Lefkovits I (ed) Immunology methods manual, vol 2, Sec. 9.4. Academic Press, London, pp 603-610
22. AL Cox J Skipper Y Chen RA Henderson TL Darrow J Shabanowitz VH Engelhard DF Hunt CL Slingluff Jr 1995 Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264 716 719 10.1126/science.7513441
23. W Wang LR Meadow JM den Haan NE Sherman Y Chen E Blokland J Shabanowitz A Agulnik RC Hendrickson CE Bishop DF Hunt E Goulmy VH Engelhard 1995 Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein Science 269 1588 1590 10.1126/science.7667640 7667640 1:CAS:528:DyaK2MXotVOgtrY%3D
24. DF Hunt JR Yates J Shabanowitz S Winston CR Hauer 1986 Protein sequencing by tandem mass spectrometry Proc Natl Acad Sci USA 83 6233 6237 10.1073/pnas.83.17.6233 3462691 1:CAS:528:DyaL28Xls1ygsrY%3D (Pubitemid 17174712)
25. JC Skipper RC Hendrickson PH Gulden V Brichard A Van Pel Y Chen J Shabanowitz T Wolfel CL Slingluff Jr T Boon DF Hunt VH Engelhard 1996 An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post- translational modification and suggests a novel pathway for processing of membrane proteins J Exp Med 183 527 534 10.1084/jem.183.2.527 8627164 1:CAS:528:DyaK28Xht1Snt70%3D (Pubitemid 26059516)
26. CC Bergmann Q Yao CK Ho SL Buckwold 1996 Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes J Immunol 157 3242 3249 8871618 1:CAS:528:DyaK28Xmtlahtbs%3D
27. U Gileadi A Gallimore P Van der Bruggen V Cerundolo 1999 Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes Eur J Immunol 29 2213 2222 10.1002/(SICI)1521-4141(199907) 29:07<2213::AID-IMMU2213>3.0.CO;2-8 10427984 1:CAS:528:DyaK1MXksFCrsLY%3D (Pubitemid 29313096)
28. AL Rakhmilevich K Janssen J Turner J Culp NS Yang 1997 Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12 Hum Gene Ther 8 1303 1311 10.1089/hum.1997.8.11-1303 9295125 1:CAS:528:DyaK2sXlsVCktLo%3D
29. T Tuting A Gambotto AB De Leo MT Lotze PD Robbins WJ Storkus 1998 Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice Cancer Gene Therapy 6 73 80 10.1038/sj.cgt.7700020
30. T Tüting A Gambotto PD Robbins WJ Storkus AB De Leo 1999 Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor Ag β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen Gene Therapy 6 629 636 10.1038/sj.gt.3300859 10476222 (Pubitemid 29192671)
31. MA Nishitani T Sakai K Ishii M Zhang Y Nakano Y Nitta J Miyazaki HO Kanayama S Kagawa K Himeno 2002 A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells Cancer Gene Ther 9 156 163 10.1038/sj.cgt.7700419 11857033 1:CAS:528:DC%2BD38XhsVSntLk%3D
32. K Falk O Rotzschke S Stevanovi G Jung HG Rammensee 1991 Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules Nature 351 290 296 10.1038/351290a0 1709722 1:CAS:528:DyaK3MXkt1Ogs78%3D
33. E Gilboa 2007 DC-based cancer vaccines J Clin Invest 117 1195 1203 10.1172/JCI31205 17476349 1:CAS:528:DC%2BD2sXlt1Omtrc%3D (Pubitemid 46718404)
34. B Weide C Garbe HG Rammensee S Pascolo 2008 Plasmid DNA- and messenger RNA-based anti-cancer vaccination Immunol Lett 115 33 42 10.1016/j.imlet.2007. 09.012 18006079 1:CAS:528:DC%2BD1cXhtlejsw%3D%3D (Pubitemid 350298588)
35. AM Bodles-Brakhop R Draghia-Akli 2008 DNA vaccination and gene therapy: optimization and delivery for cancer therapy Expert Rev Vaccines 7 1085 1101 10.1586/14760584.7.7.1085 18767956 1:CAS:528:DC%2BD1cXhtVOiur%2FL
36. W Walther R Siegel D Kobelt T Knösel M Dietel A Bembenek J Aumann M Schleef R Baier U Stein PM Schlag 2008 Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer Clin Cancer Res 14 7545 7553 10.1158/1078-0432.CCR-08-0412 19010873 1:CAS:528:DC%2BD1cXhtlylur3J
37. WW Leitner MC Baker TL Berenberg MC Lu PJ Yannie MC Udey 2009 Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen Blood 113 37 45 10.1182/blood-2008-01- 136267 18832136 1:CAS:528:DC%2BD1MXmtFSktg%3D%3D
38. YM Saenger Y Li KC Chiou B Chan G Rizzuto SL Terzulli T Merghoub AN Houghton JD Wolchok 2008 Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma Cancer Res 68 9884 9891 10.1158/0008-5472.CAN-08-2233 19047169 1:CAS:528:DC%2BD1cXhsVegtbnJ
39. Y Noguchi YT Chen LJ Old 1994 A mouse mutant p53 product recognized by CD4 + and CD8 + T cells Proc Natl Acad Sci U S A 91 3171 3175 10.1073/pnas.91.8.3171 7909159 1:CAS:528:DyaK2cXjt1Sqsro%3D
40. EV Fedoseyeva F Boisgérault NG Anosova WS Wollish P Arlotta PE Jensen SJ Ono G Benichou 2000 CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice J Immunol 164 5641 5651 10820239 1:CAS:528:DC%2BD3cXjslemsbo%3D
41. Y Noguchi EC Richards YT Chen LJ Old 1995 Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma Proc Natl Acad Sci USA 92 2219 2223 10.1073/pnas.92.6.2219 7892250 1:CAS:528:DyaK2MXksVCqtb8%3D
42. G Moeller J Adamski 2008 Integrated view on 17beta-hydroxysteroid dehydrogenases Mol Cell Endocrinol 301 7 19 10.1016/j.mce.2008.10.040 19027824 1:CAS:528:DC%2BD1MXit1Ogsb4%3D
43. V Luu-The P Tremblay F Labrie 2006 Characterization of Type 12 17-Hydroxysteroid Dehydrogenase, an Isoform of Type 3 17-Hydroxysteroid Dehydrogenase Responsible for Estradiol Formation in Women Mol Endocrinol 20 437 443 10.1210/me.2005-0058 16166196 1:CAS:528:DC%2BD28XhsVKmurs%3D (Pubitemid 43152516)
44. DS Rickman R Millon A De Reynies E Thomas C Wasylyk D Muller J Abecassis B Wasylyk 2008 Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays Oncogene 27 6607 6622 10.1038/onc.2008.251 18679425 1:CAS:528:DC%2BD1cXhtlSktLbI
45. S Nagasaki T Suzuki Y Miki J Akahira K Kitada T Ishida H Handa N Ohuchi H Sasano 2009 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis Cancer Res 69 1392 1399 10.1158/0008-5472.CAN-08-0821 19190350 1:CAS:528:DC%2BD1MXhslyns7w%3D